JPET Assistant Professor of Medicine (Clinician-Educator)

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, X.-Q.
Right arrow Articles by Masimirembwa, C. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, X.-Q.
Right arrow Articles by Masimirembwa, C. M.

Vol. 300, Issue 2, 399-407, February 2002

Amodiaquine Clearance and Its Metabolism to N-Desethylamodiaquine Is Mediated by CYP2C8: A New High Affinity and Turnover Enzyme-Specific Probe Substrate

Xue-Qing Li , Anders Björkman, Tommy B. Andersson, Marianne Ridderström and Collen M. Masimirembwa

Drug Metabolism and Pharmacokinetics and Bioanalytical Chemistry, AstraZeneca Research and Development, Mölndal, Sweden (X.-Q.L., T.B.A., M.R., C.M.M.); and Unit of Infectious Diseases, Karolinska Institute Hospital, Stockholm, Sweden (X.-Q.L., A.B., C.M.M.)

Amodiaquine (AQ) metabolism to N-desethylamodiaquine (DEAQ) is the principal route of disposition in humans. Using human liver microsomes and two sets of recombinant human cytochrome P450 isoforms (from lymphoblastoids and yeast) we performed studies to identify the CYP isoform(s) involved in the metabolism of AQ. CYP2C8 was the main hepatic isoform that cleared AQ and catalyzed the formation of DEAQ. The extrahepatic P450s, 1A1 and 1B1, also cleared AQ and catalyzed the formation of an unknown metabolite M2. The Km and Vmax values for AQ N-desethylation were 1.2 µM and 2.6 pmol/min/pmol of CYP2C8 for recombinant CYP2C8, and 2.4 µM and 1462 pmol/min/mg of protein for human liver microsomes (HLMs), respectively. Relative contribution of CYP2C8 in the formation of DEAQ was estimated at 100% using the relative activity factor method. Correlation analyses between AQ metabolism and the activities of eight hepatic P450s were made on 10 different HLM samples. Both the formation of DEAQ and the clearance of AQ showed excellent correlations (r2 = 0.98 and 0.95) with 6alpha -hydroxylation of paclitaxel, a marker substrate for CYP2C8. The inhibition of DEAQ formation by quercetin was competitive with Ki values of 1.96 for CYP2C8 and 1.56 µM for HLMs. Docking of AQ into the active site homology models of the CYP2C isoforms showed favorable interactions with CYP2C8, which supported the likelihood of an N-desethylation reaction. These data show that CYP2C8 is the main hepatic isoform responsible for the metabolism of AQ. The specificity, high affinity, and high turnover make AQ desethylation an excellent marker reaction for CYP2C8 activity.

0022-3565/02/3002-0399$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2002 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Drug Metab. Dispos.Home page
T. Johansson, U. Jurva, G. Gronberg, L. Weidolf, and C. Masimirembwa
Novel Metabolites of Amodiaquine Formed by CYP1A1 and CYP1B1: Structure Elucidation Using Electrochemistry, Mass Spectrometry, and NMR
Drug Metab. Dispos., March 1, 2009; 37(3): 571 - 579.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
S. Jeong, P. D. Nguyen, and Z. Desta
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Antimicrob. Agents Chemother., February 1, 2009; 53(2): 541 - 551.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
G. O. Adjei, K. Kristensen, B. Q. Goka, L. C. G. Hoegberg, M. Alifrangis, O. P. Rodrigues, and J. A. L. Kurtzhals
Effect of Concomitant Artesunate Administration and Cytochrome P4502C8 Polymorphisms on the Pharmacokinetics of Amodiaquine in Ghanaian Children with Uncomplicated Malaria
Antimicrob. Agents Chemother., December 1, 2008; 52(12): 4400 - 4406.
[Abstract] [Full Text] [PDF]

Home page
 J Antimicrob ChemotherHome page
M. Sousa, A. Pozniak, and M. Boffito
Pharmacokinetics and pharmacodynamics of drug interactions involving rifampicin, rifabutin and antimalarial drugs
J. Antimicrob. Chemother., November 1, 2008; 62(5): 872 - 878.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
J. A. Williams, T. Andersson, T. B. Andersson, R. Blanchard, M. O. Behm, N. Cohen, T. Edeki, M. Franc, K. M. Hillgren, K. J. Johnson, et al.
PhRMA White Paper on ADME Pharmacogenomics
J. Clin. Pharmacol., July 1, 2008; 48(7): 849 - 889.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
D. F. Echeverry, G. Holmgren, C. Murillo, J. C. Higuita, A. Bjorkman, J. P. Gil, and L. Osorio
Polymorphisms in the pfcrt and pfmdr1 Genes of Plasmodium falciparum and in Vitro Susceptibility to Amodiaquine and Desethylamodiaquine
Am J Trop Med Hyg, December 1, 2007; 77(6): 1034 - 1038.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
K. Abass, P. Reponen, M. Turpeinen, J. Jalonen, and O. Pelkonen
Characterization of Diuron N-Demethylation by Mammalian Hepatic Microsomes and cDNA-Expressed Human Cytochrome P450 Enzymes
Drug Metab. Dispos., September 1, 2007; 35(9): 1634 - 1641.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
L. N. Markham, E. Giostra, A. Hadengue, M. Rossier, M. Rebsamen, and J. Desmeules
Emergency Liver Transplantation in Amodiaquine-Induced Fulminant Hepatitis
Am J Trop Med Hyg, July 1, 2007; 77(1): 14 - 15.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Volotinen, M. Turpeinen, A. Tolonen, J. Uusitalo, J. Maenpaa, and O. Pelkonen
Timolol Metabolism in Human Liver Microsomes Is Mediated Principally by CYP2D6
Drug Metab. Dispos., July 1, 2007; 35(7): 1135 - 1141.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
C. J. O'Donnell, K. Grime, P. Courtney, D. Slee, and R. J. Riley
The Development of a Cocktail CYP2B6, CYP2C8, and CYP3A5 Inhibition Assay and a Preliminary Assessment of Utility in a Drug Discovery Setting
Drug Metab. Dispos., March 1, 2007; 35(3): 381 - 385.
[Abstract] [Full Text] [PDF]

Home page
 J Clin PharmacolHome page
R. L. Walsky, E. A. Gaman, and R. S. Obach
Examination of 209 Drugs for Inhibition of Cytochrome P450 2C8
J. Clin. Pharmacol., January 1, 2005; 45(1): 68 - 78.
[Abstract] [Full Text] [PDF]

Home page
 Am J Trop Med HygHome page
A. AUBOUY, J. MAYOMBO, A. KEUNDJIAN, M. BAKARY, J. LE BRAS, and P. DELORON
SHORT REPORT: LACK OF PREDICTION OF AMODIAQUINE EFFICACY IN TREATING PLASMODIUM FALCIPARUM MALARIA BY IN VITRO TESTS
Am J Trop Med Hyg, September 1, 2004; 71(3): 294 - 296.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
M. Turpeinen, R. Nieminen, T. Juntunen, P. Taavitsainen, H. Raunio, and O. Pelkonen
SELECTIVE INHIBITION OF CYP2B6-CATALYZED BUPROPION HYDROXYLATION IN HUMAN LIVER MICROSOMES IN VITRO
Drug Metab. Dispos., June 1, 2004; 32(6): 626 - 631.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
R. L. Walsky and R. S. Obach
VALIDATED ASSAYS FOR HUMAN CYTOCHROME P450 ACTIVITIES
Drug Metab. Dispos., June 1, 2004; 32(6): 647 - 660.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
B. Ma, R. Subramanian, M. L. Schrag, A. D. Rodrigues, and C. Tang
CYTOCHROME P450 2C8 (CYP2C8)-MEDIATED HYDROXYLATION OF AN ENDOTHELIN ETA RECEPTOR ANTAGONIST IN HUMAN LIVER MICROSOMES
Drug Metab. Dispos., May 1, 2004; 32(5): 473 - 478.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
G. A. Schoch, J. K. Yano, M. R. Wester, K. J. Griffin, C. D. Stout, and E. F. Johnson
Structure of Human Microsomal Cytochrome P450 2C8: EVIDENCE FOR A PERIPHERAL FATTY ACID BINDING SITE
J. Biol. Chem., March 5, 2004; 279(10): 9497 - 9503.
[Abstract] [Full Text] [PDF]

Home page
 Drug Metab. Dispos.Home page
D. Projean, B. Baune, R. Farinotti, J.-P. Flinois, P. Beaune, A.-M. Taburet, and J. Ducharme
IN VITRO METABOLISM OF CHLOROQUINE: IDENTIFICATION OF CYP2C8, CYP3A4, AND CYP2D6 AS THE MAIN ISOFORMS CATALYZING N-DESETHYLCHLOROQUINE FORMATION
Drug Metab. Dispos., June 1, 2003; 31(6): 748 - 754.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2002 by the American Society for Pharmacology and Experimental Therapeutics.